Ράμμα GV PGLA 3/0, 90cm με βελόνα 1/2 κύκλου, tapercut 24mm.

Απορροφήσιμο χειρουργικό ράμμα με ή χωρίς βελόνα - Το PGLA είναι ένα αποστειρωμένο απορροφήσιμο συνθετικό, πολύνηματο χειρουργικό ράμμα. Το υλικό επικάλυψης είναι πολυ(γλυκολίδιο-συν-λακτίδιο) και στεατικό ασβέστιο. Το ράμμα πληροί όλες τις απαιτήσεις της Φαρμακοποιίας των Ηνωμένων Πολιτειών (USP) και της Ευρωπαϊκής Φαρμακοποιίας (EP) για απορροφήσιμα χειρουργικά ράμματα.PGLA - Instruction for Use I．Description PGLA is a sterile, absorbable synthetic, multifilament surgical suture composed of Poly(glycolide-co lactide) (（C21H16NO3）n). The sutures coating material is polycaprolactone and calcium stearate. PGLA suture meets all the requirements of United States Pharmacopoeia (USP) and European Pharmacopoeia (EP) for absorbable surgical sutures. II．Indications The suture is indicated for use in soft tissue approximation and/or ligation but not for use in cardiovascular tissue and neurological tissue. III．Action A slight tissue inflammation may occur when PGLA Sutures are placed in tissue, which is characteristic of foreign body response followed by gradual encapsulation by connective tissue. PGLA Sutures have a high initial tensile strength. 75% of the original tensile strength is retained upto 14 days after surgery, 50% of the original tensile strength is retained at the end of three weeks post implantation. Absorption of PGLA suture is minimal upto 10% in two weeks, and absorption is essentially complete between 56 and 70 days. IV．Adverse Reactions: Adverse effects associated with use of PGLA include allergic response in certain patients, transient local irritation at the wound site, transient inflammatory foreign body response, erythema and induration during the absorption process of subcuticular sutures. V．Contraindications The sutures should not be used : 1. In cardiovascular and neurological tissues 2. In patients who are allergic to its components.